CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the closing of its previously announced public offering of 2,300,000 of shares of common stock at a public offering price of $24.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 300,000 additional shares of common stock.
The net proceeds to CareDx from the offering are expected to be approximately $52.8 million, after deducting underwriting discounts and commissions and estimated offering expenses. Jefferies and Piper Jaffray acted as joint book-running managers for the offering. Craig-Hallum acted as co-manager for the offering. The securities described above were offered by CareDx pursuant to a shelf registration statement on Form S-3 (File No. 333-227168) previously filed with the Securities and Exchange Commission (the SEC) on August 31, 2018, as amended by Amendment No. 1 thereto previously filed with the SEC on October 10, 2018, and declared effective on October 11, 2018. A final prospectus supplement and accompanying prospectus related to the offering was filed with the SEC on November 14, 2018 and is available on the SECs website at https://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by e-mail at [email protected] or by telephone at (877) 821-7388; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by email at [email protected], or by phone at (800) 747-3924. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such …
[Read on via official release]
Source: US SEC
View full document: